Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531133 | 0.93 | TACR1 (0.44) | TACR1DPP4DPP8DPP9DPP7 | |
| SCHEMBL6053005 | 0.88 | TACR1 (0.40) | TACR1DPP4SIRT1SMN1; SMN2DPP8 | |
| SCHEMBL6494918 | 0.88 | TACR1 (0.40) | TACR1DPP4SIRT1SMN1; SMN2DPP8 | |
| SCHEMBL6052769 | 0.83 | TACR1 (0.38) | TACR1DPP4SIRT1GAAACE | |
| SCHEMBL7835398 | 0.83 | TACR1 (0.38) | TACR1DPP4SIRT1GAAACE | |
| SCHEMBL7528040 | 0.83 | TACR1 (0.38) | TACR1DPP4SIRT1GAAACE | |
| SCHEMBL3141190 | 0.83 | TACR1 (0.38) | TACR1DPP4SIRT1GAAACE | |
| SCHEMBL2675548 | 0.83 | TACR1 (0.38) | TACR1DPP4SIRT1GAAACE | |
| SCHEMBL6838967 | 0.81 | DPP4 (0.40) | TACR1DPP4SIRT1CYP2C19SMN1; SMN2 | |
| SCHEMBL4086816 | 0.80 | TACR1 (0.44) | TACR1DPP4CYP2C19SMN1; SMN2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
| EP-1032424-B9 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| JP-2003526654-A | — | — | 2003-09-09 | — | — | JP | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-6555569-B2 | Especially for treatment of Chlamydia pneumoniae | PFIZER INC. | 2003-04-29 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| EP-1032424-B1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2001-09-12 | — | — | EP | claimed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1061074-A1 | Novel process and intermediates | Pfizer Products Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| EP-1032424-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-1999026659-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | TACR1 256/4885DPP4 1474/4885SIRT1 1113/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | TACR1 189/4885DPP4 1600/4885SIRT1 732/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | TACR1 1523/4885DPP4 206/4885SIRT1 667/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | TACR1 1045/4885DPP4 1574/4885SIRT1 458/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | TACR1 190/4885DPP4 1024/4885SIRT1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.